Publications by authors named "Franck Audemar"
Article Synopsis
- The study investigates the prevalence and incidence of hepatitis E virus (HEV) infection in patients with inflammatory bowel disease (IBD) undergoing immunomodulatory treatment, given that these medications can compromise the immune system.
- Conducted across 16 French centers, the research involved 488 IBD patients, revealing very few cases of acute HEV infection, with a seroprevalence of 14.2% for chronic infection, particularly among older patients and those with higher seafood intake.
- The findings suggest that routine HEV screening isn't necessary for IBD patients on immunomodulators, but HEV should be tested if liver abnormalities occur.
Background: Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are available on the routine daily management of advanced gastric or gastroesophageal junction cancers.
View Article and Find Full Text PDFIntroduction: In patients with unresectable liver metastases from colorectal cancer (CRCLM), systemic doublet or triplet chemotherapy and targeted therapy is considered a standard first-line treatment. Hepatic arterial infusion of oxaliplatin (HAI-ox) generates a high response rate, but this still needs to be confirmed in a randomized trial. We incorporated HAI-ox in doublet or triplet + targeted therapy to validate its efficacy.
View Article and Find Full Text PDFBackground: Colorectal cancer (CRC) patients have a better prognosis if metastases are resectable. Initially, unresectable liver-only metastases can be converted to resectable with chemotherapy plus a targeted therapy. We assessed which of chemotherapy doublet (2-CTx) or triplet (3-CTx), combined with targeted therapy by RAS status, would be better in this setting.
View Article and Find Full Text PDFBackground And Aims: There is limited data regarding the role for systemic treatment in patients with Hepatocellular Carcinoma with Child-Pugh B cirrhosis.
Methods: PRODIGE 21 was a multicentric prospective non-comparative randomized trial. Patients were randomized to receive sorafenib (Arm A), pravastatin (Arm B), sorafenib-pravastatin (Arm C) combination, or best supportive care (Arm D).
Article Synopsis
- * Results showed that a baseline splenic volume greater than 180 mL linked to poorer progression-free survival (PFS) but had no significant impact on overall survival (OS).
- * Additionally, larger splenic volume correlated with higher levels of circulating myeloid-derived suppressor cells (mMDSC), indicating that splenomegaly may reflect immune system changes in these patients.
Background: Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection. Unfortunately, only 10-15% of CRLM are initially considered resectable.
View Article and Find Full Text PDF